Drug Type Synthetic peptide |
Synonyms- |
Target |
Action inhibitors |
Mechanism Respiratory syncytial virus F protein inhibitors |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Respiratory Syncytial Virus Infections | Phase 2 | China | 04 Sep 2026 | |
| Human Metapneumovirus Infection | IND Approval | United States | 24 Mar 2026 |






